Table 1. Clinical features of patients with IVIGRKD.
| Variables | Responsive (A) | Resistant (B) | U/X2 | P | |||
|---|---|---|---|---|---|---|---|
| n | median (p25-p75)/n(%) | n | median (p25-p75)/n(%) | ||||
| Male-to-female ratio | 1746 | 1.52: 1 | 380 | 2.06: 1 | 6.57 | 0.01 | |
| Age | ≤ 6 months, % | 1746 | 275 (15.8) | 380 | 43 (11.3) | 4.965 | 0.084 |
| 6 month-5years, % | 1232 (70.6) | 285 (75.0) | 4.965 | 0.084 | |||
| > 5 years, % | 239 (13.7) | 52 (13.7) | 4.965 | 0.084 | |||
| illness days at admission, days | 1746 | 6 (5–7) | 380 | 6 (4–7) | –1.048 | 0.295 | |
| Number of major dignostic criteria | 1746 | 4 (3–5) | 380 | 4 (3–5) | –0.703 | 0.482 | |
| Days of illness at initial IVIG treatmetn, days | 1746 | 6 (5–8) | 380 | 6 (5–7) | –3.948 | < 0.001 | |
| Total fever duration, days | 1746 | 7 (6–8) | 380 | 9 (7–10) | –11.204 | < 0.001 | |
| Days of hospitalization, days | 1746 | 6 (5–8) | 380 | 9 (7–13) | –18.918 | < 0.001 | |
| incomplete KD, % | 1746 | 1025 (58.7) | 380 | 214 (56.3) | 0.733 | 0.212 | |
| Delayed diagnosis, % | 1746 | 126 (7.2) | 380 | 39 (10.3) | 4.046 | 0.031 | |
| CALs, % | 1735 | 370 (21.3) | 380 | 118 (31.1) | 16.617 | < 0.001 | |
| ESR, mm/h | 1584 | 64 (44–88) | 360 | 73 (44–95) | –2.629 | 0.009 | |
| CRP, mg/L | 1592 | 72 (34–122) | 364 | 89 (45–157) | –4.526 | < 0.001 | |
| WBC, × 109/L | 1608 | 12.4 (8.9–16.3) | 364 | 13.4 (9.3–18.2) | –3.14 | 0.002 | |
| NE, % | 1608 | 60.9 (46.1–73.3) | 364 | 68.2 (51.9–82.3) | –6.56 | < 0.001 | |
| Absolute NE, × 109/L | 1608 | 7.4 (4.3–11.1) | 364 | 8.5 (5.5–13.4) | –5.008 | < 0.001 | |
| LY, % | 1608 | 28.5 (18.8–41.1) | 364 | 21.2 (11.4–35.5) | –7.185 | < 0.001 | |
| Absolute LY, × 109/L | 1608 | 3.3 (2.2–4.7) | 364 | 2.7 (1.5–4.2) | –5.339 | < 0.001 | |
| NLR, | 1608 | 2.2 (1.1–3.8) | 364 | 3.3 (1.5–7.1) | –7.001 | < 0.001 | |
| EO, % | 1604 | 2.3 (1.0–4.5) | 363 | 1.8 (0.7–3.6) | –4.03 | < 0.001 | |
| Absolute EO, × 109/L | 1604 | 0.28 (0.12–0.52) | 363 | 0.23 (0.09–0.48) | –2.514 | 0.012 | |
| MO, % | 1604 | 5.6 (3.4–8.2) | 363 | 5.4 (2.9–8.1) | –1.414 | 0.157 | |
| Absolute MO, × 109/L | 1604 | 0.66 (0.40–1.01) | 363 | 0.68 (0.39–1.09) | –0.824 | 0.41 | |
| Hemoglobin, g/L | 1607 | 107 (100–114) | 363 | 107 (99–113) | –1.101 | 0.271 | |
| Platelet, × 109/L | 1607 | 368 (291–460) | 363 | 343 (258–445) | –3.28 | 0.001 | |
| ALT, U/L | 1702 | 21 (12–46) | 375 | 29 (14–78) | –4.96 | < 0.001 | |
| AST, U/L | 1702 | 30 (23–43) | 375 | 34 (24–56) | –4.25 | < 0.001 | |
| Albumin, g/L | 1702 | 36.5 (33.7–39.1) | 375 | 35.3 (31.3–38.4) | –5.017 | < 0.001 | |
| TBil, μmol/L | 1701 | 4.3 (2.9–6.5) | 375 | 5.3 (3.4–10.3) | –5.962 | < 0.001 | |
| GGT, U/L | 1701 | 21 (10–68) | 375 | 35 (13–102) | –4.749 | < 0.001 | |
| Sodium, mmol/L | 1590 | 137 (134–139) | 348 | 135 (133–138) | –7.418 | < 0.001 | |
| Chloride, mmol/L | 1589 | 105 (103–108) | 347 | 105 (102–107) | –0.998 | 0.318 | |
| Potassium, mmol/L | 1590 | 3.7 (3.4–4.1) | 348 | 3.6 (3.2–4.0) | –4.047 | < 0.001 | |
| Calcium, mmol/L | 1588 | 1.13 (1.07–1.19) | 346 | 1.12 (1.06–1.18) | –2.121 | 0.034 | |
IVIGRKD: intravenous immunoglobin–resistant Kawasaki Disease, CALs: coronary artery lesions, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, WBC: white blood cell count, NE: neutrophils, LY: lymphocytes, NLR: neutrophil-to-lymphocyte ratio, EO: eosionphils, MO: monocytes, ALT: alanine aminotransferase, AST: aspartate transaminase, TBil: total bilirubin, GGT: gamma-glutamyl transferase.